Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
WRAL Documentary Easy Targets: Gangs getting younger in NC
Recommended
Hurricane season 2024: Beware rip current danger if you visit NC coast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
20.75
-1.35 (-6.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed
November 23, 2022
Via
Benzinga
Recap: Bicycle Therapeutics Q3 Earnings
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
August 22, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
August 31, 2022
Upgrades
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
August 22, 2022
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83...
Via
Benzinga
Bicycle Therapeutics: Q2 Earnings Insights
August 04, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Where Bicycle Therapeutics Stands With Analysts
July 06, 2022
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 24, 2022
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press...
Via
Benzinga
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
June 08, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
Bicycle Therapeutics
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
June 06, 2022
Monday's session saw 84 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.